OmniAb Inc. (OABI) - Cash Flow Conversion Efficiency
Based on the latest financial reports, OmniAb Inc. (OABI) has a cash flow conversion efficiency ratio of -0.019x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.91 Million) by net assets ($262.65 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See OmniAb Inc. balance sheet quality to measure how much of total assets are equity-financed.
OmniAb Inc. - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how OmniAb Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Check OmniAb Inc. cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
OmniAb Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of OmniAb Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Schweizerische Nationalbank
SW:SNBN
|
0.000x |
|
Sungwoo Hitech Co. Ltd
KQ:015750
|
0.037x |
|
Energy Services Of America Corp
NASDAQ:ESOA
|
0.045x |
|
Richtech Robotics Inc. Class B Common Stock
NASDAQ:RR
|
-0.005x |
|
Funko Inc
NASDAQ:FNKO
|
0.060x |
|
Vinacafe Bien Hoa JSC
VN:VCF
|
-0.043x |
|
FM Mattsson Mora Group AB (publ)
ST:FMM-B
|
0.007x |
|
Pss Co Ltd
TW:6914
|
0.236x |
Annual Cash Flow Conversion Efficiency for OmniAb Inc. (2019–2025)
The table below shows the annual cash flow conversion efficiency of OmniAb Inc. from 2019 to 2025. For the full company profile with market capitalisation and key ratios, see OmniAb Inc. (OABI) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $267.03 Million | $-36.45 Million | -0.137x | +1.00% |
| 2024-12-31 | $287.62 Million | $-39.66 Million | -0.138x | -1948.44% |
| 2023-12-31 | $314.58 Million | $2.35 Million | 0.007x | +171.00% |
| 2022-12-31 | $341.37 Million | $-3.59 Million | -0.011x | +56.59% |
| 2021-12-31 | $234.31 Million | $-5.67 Million | -0.024x | -257.55% |
| 2020-12-31 | $235.54 Million | $3.62 Million | 0.015x | +164.53% |
| 2019-12-31 | $218.19 Million | $-5.20 Million | -0.024x | -- |
About OmniAb Inc.
OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada. The company's technology platform creates and screens diverse antibody repertoires to identify optimal antibodies and other target-binding proteins for partne… Read more